Pioneering a new wave of oncology treatment

Immuno-oncology meets global science and big data

About EXUMA Biotech

EXUMA Biotech is a clinical-stage biotechnology company discovering and developing Chimeric Antigen Receptor (CAR)-T cell products for solid tumors.

CAR-T cell therapy has already delivered remarkable on-target responses to certain hematological malignancies through a complex manufacturing process. Through our logic gated CAR-T platform, we are taking cellular therapies to the next step by harnessing the power of the immune system to target some of the most challenging solid tumor malignancies, and building CAR-T delivery platforms that may enable more patients to access cellular therapies in the future.

Innovation is at the core of our global network

From West Palm Beach to Grand Cayman to Shanghai: We are integrated over 12 hours of time zones because cancer never sleeps, and neither does the data.

Same-day CAR-T therapy

We are revolutionizing CAR-T administration via our next-generation rapid point-of-care, or “rPOC”, subcutaneous, same-day delivery platform. In the fight against cancer, our global teams are collaborating to develop this first of its kind “off the shelf” treatment, making same-day CAR-T a reality for all cancer patients.